Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 5:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 2,037 matching trials from the live ClinicalTrials.gov search.
Conditions
Leiomyosarcoma, Sarcoma
Interventions
all-trans retinoic acid, Cemiplimab, Computed Tomography, Magnetic resonance imaging, Biospecimen Collection
Drug · Procedure
Lead sponsor
Gabriel Tinoco
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Urticaria Pigmentosa
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 18 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
End of Life, Cancer
Interventions
Receive technology-based supportive cancer care, Receive redesigned team-based supportive cancer care
Other · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
2,996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
17
States / cities
Birmingham, Alabama • Mobile, Alabama • Duarte, California + 11 more
Conditions
Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus, T/NK-lymphoproliferative Disease, Nasopharyngeal Carcinoma, Smooth Muscle Tumor
Interventions
MABEL CTLs, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
2
States / cities
Houston, Texas
Conditions
Localized Osteosarcoma, Metastatic Osteosarcoma
Interventions
Cisplatin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate, Peginterferon Alfa-2b, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery
Drug · Biological · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
5 Years to 40 Years
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
186
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 132 more
Conditions
Sarcoma, Soft Tissue, Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Myxofibrosarcoma, Angiosarcoma, Fibrosarcoma, Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma
Interventions
Dexrazoxane, Doxorubicin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Sarcoma, Thoracic Cancer, Abdominal Cancer, Pelvic Cancer
Interventions
Stereotactic body radiotherapy, Research blood draw
Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
trastuzumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Soft Tissue Sarcoma
Interventions
18F-FMISO
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Oral Complications, Ovarian Cancer, Pain, Sarcoma
Interventions
management of therapy complications, pain therapy
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Advanced Solid Tumor
Interventions
M3554
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Conditions
Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
42
States / cities
Buena Park, California • Los Angeles, California • Newport Beach, California + 28 more
Conditions
Neuroblastoma, Osteosarcoma
Interventions
iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Months and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2044
U.S. locations
2
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina
Conditions
Leiomyosarcoma
Interventions
Lurbinectedin, Doxorubicin
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 18 more
Conditions
Osteosarcoma, Ewing's Sarcoma, Neuroblastoma, Brain Tumors, Leukemia
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Cleveland, Ohio
Conditions
Localized Extraskeletal Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions
Cyclophosphamide, Dexrazoxane, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Laboratory Biomarker Analysis, Topotecan Hydrochloride, Vincristine Sulfate
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 50 Years
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
215
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 149 more
Conditions
Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma
Interventions
Microwave Ablation
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Duarte, California • Rochester, Minnesota • New York, New York + 2 more
Conditions
Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma
Interventions
BLU-222, Carboplatin, Ribociclib, Fulvestrant
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
19
States / cities
Little Rock, Arkansas • San Francisco, California • Stanford, California + 13 more
Conditions
Melanoma, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer, Breast Cancer
Interventions
IDC-G305
Biological
Lead sponsor
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 1 more
Conditions
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
Interventions
Nivolumab, Azacitidine, Post Treatment Surgery
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
Up to 39 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 19 more
Conditions
Thrombocytopaenia
Interventions
eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
7
States / cities
Santa Monica, California • Miami, Florida • Tampa, Florida + 4 more
Conditions
Advanced Angiosarcoma
Interventions
TRC105, Votrient
Biological · Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
26
States / cities
Tucson, Arizona • Palo Alto, California • Santa Monica, California + 22 more
Conditions
Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interventions
belinostat, carboplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
81
States / cities
Hartford, Connecticut • New Britain, Connecticut • Lewes, Delaware + 53 more
Not yet recruiting No phase listed Observational

Tumor-Lymph Node Mapping

NCT07054944
Conditions
Pediatric Solid Tumors, Rhabdomyosarcoma, Sarcoma, Germ Cell Tumor
Interventions
ICG (Indocyanine Green)
Diagnostic Test
Lead sponsor
University of Rochester
Other
Eligibility
1 Month to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, New York